Contact

Dr. Barbara Wenzel
Neuroradiopharmaceuticals
b.wenzelAthzdr.de
Phone: +49 351 260 - 4637, 4625

Dr. Winnie Deuther-Conrad
Department Head
Neuroradiopharmaceuticals
w.deuther-conradAthzdr.de
Phone: +49 351 260 - 4613

Prof. Dr. Peter Brust
Department Head
Neuroradiopharmaceuticals
p.brustAthzdr.de
Phone: +49 351 260 - 4610
Fax: +49 351 260 - 4699

Molecular imaging of adenosine signalling in cancer

Research

While intracellular adenosine is a key molecule in energy metabolism, extracellular adenosine is a potent regulator of intracellular signaling affecting different physiological functions. The immunosuppressive effects of adenosine as well as the adenosine-triggered activation of catabolic energy production account for the pro-cancer roles of extracellular adenosine. Accordingly, adenosine receptors such as the A2B receptor – expressed on immune and endothelial cells only at elevated levels of adenosine – have been identified as potential new targets in cancer immunotherapy. Because the expression of the biological target in the patient is a prerequisite for response of targeted therapies, non-invasive assessment of the receptor expression and accessibility is essential. Accordingly, together with our partners of the University of Bonn and ROTOP Pharmaka GmbH, we designed and evaluated the first 18F-labelled radioligand for imaging the adenosine A2B receptor by PET.

The development of the new radioligand [18F]PA51 is based on a lead compound with a pyrazine scaffold, having a high affinity and selectivity towards this adenosine receptor subtype. Biodistribution and radiotracer metabolism of [18F]PA51 were assessed in mice to investigate the brain uptake and in vivo stability.

Besides, we apply our expertise in medicinal chemistry and radiochemistry to the development and validation of new radioligands of the adenosine A2A receptor. In a common research project with partners of the University of Dresden and ROTOP Pharmaka GmbH, we work on the investigation of alterations in adenosine receptor signaling by means of small animal PET/MRI studies in murine brain disease models.

Partners

  • Pharma Center Bonn, University of Bonn (Prof. Christa E. Müller, Dr. Sonja Hinz)
  • Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden (Prof. Richard H.W. Funk, Prof. Heinz Reichmann, Dr. Francisco Pan-Montojo)
  • ROTOP Pharmaka GmbH, Dresden (Jens Junker, Dr. Cathleen Juhl)

Financial support

  • BMBF (German Federal Ministry for Education and Research) within the BioPharma initiative “Neuroallianz”
  • SAB (Sächsische Aufbaubank)
   

Publications

  • Development of the first fluorine-18 labelled radioligand for imaging of the adenosine A2B receptor

    Lindemann M, Wenzel B, Hinz S, Dukic-Stefanovic S, Deuther-Conrad W, Teodoro R, Juhl C, Müller C, Brust P, Steinbach J. Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 60 Issue S1 Supplement: The 22nd International Symposium on Radiopharmaceutical Sciences (ISRS 2017), Dresden, Germany, May 14-19, 2017

  • Entwicklung des ersten F-18-markierten Radioliganden zur molekularen Bildgebung des Adenosinrezeptors A2B im Gehirn

    Lindemann M, Wenzel B, Hinz S, Dukic-Stefanovic S, Deuther-Conrad W, Teodoro R, Juhl C, Müller C, Brust P, Steinbach J. Nuklearmedizin 56(2017)2, A45


Contact

Dr. Barbara Wenzel
Neuroradiopharmaceuticals
b.wenzelAthzdr.de
Phone: +49 351 260 - 4637, 4625

Dr. Winnie Deuther-Conrad
Department Head
Neuroradiopharmaceuticals
w.deuther-conradAthzdr.de
Phone: +49 351 260 - 4613

Prof. Dr. Peter Brust
Department Head
Neuroradiopharmaceuticals
p.brustAthzdr.de
Phone: +49 351 260 - 4610
Fax: +49 351 260 - 4699